We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pip3.0
Piperlongumine Research
Mostly mechanism / observational
7 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Piperlongumine studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2013–2026.
Based on 7 studies
Confidence
Low confidence
By outcome
Cancer (preclinical)
Mostly mechanism / observational3 studies
Safety profile
Mostly mechanism / observational3 studies
Senescence & healthspan (preclinical)A natural senolytic that clears senescent cells in vitro; no human efficacy data and poor oral bioavailability. · Not established (no human data)
Too few graded studies2 studies
Steady research
2 studies in the last 5 years
201320192026
1Review2026
In plain English: By bridging ancient knowledge with modern innovations, this review highlights P. longum as a versatile candidate for integrative medicine and novel drug delivery strategies.
Bhatia A, Mehta J, Hashmi AR, Sekar M, Bandyopadhyay A, Pal T, Kumar BRP, Mat Rani NNI, Wong LS, Kumarasamy V. · Drug design, development and therapy (2026)
Furthermore, advances in nanotechnology including liposomes, cubosomes, and transgelosomes, have enhanced its solubility, bioavailability, and targeted pharmacological efficacy.
Industrial applications span nutraceuticals, phytopharmaceuticals, and green nanotechnology, underscoring its potential for commercialization.
Clinical and preclinical studies validate its efficacy and safety within therapeutic ranges.
In plain English: Piperlongumine selectively killed cancer cells by targeting the stress response to ROS and synergized with cisplatin in vitro and in vivo.
Roh, Kim, Park, Kim, Kwon, Lee · Oncotarget (2014)
Selectively killed head-and-neck cancer cells (regardless of p53 status) while sparing normal cells
Raised ROS; cytotoxicity was blocked by the antioxidant N-acetylcysteine, confirming the ROS mechanism
Inhibited tumor growth and synergized with cisplatin in mouse xenografts (in vivo)
In plain English: Piperlongumine shows selective preclinical anticancer activity via ROS accumulation and glutathione depletion, with nanoformulation needed to overcome poor bioavailability.
Tripathi, Biswal · Pharmacological research (2020)
In plain English: Piperlongumine and its derivatives show preclinical anticancer promise, with ongoing work on analogs and delivery to overcome pharmacokinetic limitations.
Swain, Sahoo · Archiv der Pharmazie (2024)
Recent review of piperlongumine and synthetic derivatives as anticancer leads
Summarizes the parent compound's mechanism and the push toward derivatives/delivery systems
Underscores that translation is limited by pharmacokinetics — still no clinical efficacy
In plain English: Piplartine is selectively cytotoxic to cancer cells via oxidative stress and inhibits tumor growth in mice, with chronic toxicology still needed before clinical trials.
Bezerra, Pessoa, de Moraes, Saker-Neto, Silveira, Costa-Lotufo · European journal of pharmaceutical sciences (2013)
Foundational review of piplartine/piperlongumine's chemistry and broad preclinical pharmacology
Anticancer activity (selective oxidative-stress-driven cytotoxicity, antitumor in mice) is its most promising property
Flags that chronic toxicology is still needed to support clinical trials — i.e. no human efficacy yet